Researchers identified a handful of prognostic factors to create a synthetic control arm, which can ultimately replace placebo control arms in future trials of salvage-line metastatic CRC.
Multicenter VOLTAGE-2 Phase II Trial Will Conduct Exploratory Biomarker Analysis Using Highly-Sensitive Genomic Platforms from Personalis
. | May 16, 2023